Windlas Biotech Limited IPO
MainboardPharmaceuticals & Drugs
Listed On: Aug 16, 2021 at ₹ 437 (NSE)
₹ 13800 /30 Shares
Check Allotment04 Aug, 2021
Open Date06 Aug, 2021
Close Date11 Aug, 2021
Allotment Date16 Aug, 2021
Listing DatePrice Summary
Last Closing
776.65 (68.84%)52 Week High
1,140.0052 Week Low
665.10Last Update
19-Dec-2025 3:30 PMIPO Issue Details
- Issue Price ₹448-460 per equity share
- Face Value ₹5 Per Equity Share
- Issue Price ₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares
- Listing at BSE, NSE
- List Price 437 (NSE)
- Listing Date 2021-08-16
- Lead Manager SBI Capital Markets Limited, DAM Capital Advisors Limited, IIFL Securities Limited
- Registrar Link Intime India Private Limited
IPO Details
- Retail Portion 35%
IPO Details
The IPO of is priced at ₹448-460 per equity share, which has a face value of ₹5 Per Equity Share each, IPO bidding starts from Aug 4, 2021 and ends on Aug 6, 2021. The allotment for IPO will be finalized on Aug 11, 2021. IPO will be listed on BSE, NSE, with a tentative listing date fixed as Aug 16, 2021. The company shall list its equity shares on the BSE, NSE. Link Intime India Private Limited is the registrar of the issue.
The book-running lead manager for the IPO is/are SBI Capital Markets Limited, DAM Capital Advisors Limited, IIFL Securities Limited.
The IPO sets its price band at 448-460 for each share. A single application for Windlas Biotech Limited IPO must contain at least 30 shares.
Read More
IPO Subscription Analysis And Details
| As on | QIB | NII | Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 17,45,804 | 13,09,354 | 30,55,159 | 61,10,317 |
|
Day 1
04-08-21 05:00 PM
|
0.00 x | 0.34 | 6.22 x | 3.18 x |
|
Day 2
05-08-21 05:00 PM
|
0.04 x | 1.11 | 13.40 x | 7.00 x |
|
Day 3
06-08-21 08:00 PM
|
24.10 x | 15.91 | 24.27 x | 22.47 x |
Valuations
Company Financials
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
|---|---|---|---|---|
| Assets | 296.12 | 338.48 | 198.18 | 298.88 |
| Revenue | 430.69 | 331.33 | 311.52 | 356.57 |
| Profit After Tax | 15.57 | 16.21 | 63.82 | 11.19 |
About Company
Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facility is located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
- Promoter(s)
Ashok Kumar Windlass
Hitesh Windlass
Manoj Kumar Windlass
AKW WBL Family Pvt Trust
Pre Issue Share Holding : 78%
Post Issue Share Holding : 65.16%
IPO - Issue Objectives
Purchase of equipment required for (i) capacity expansion of our existing facility at Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant-II;
General Corporate Purpose
To meet issue expenses
Repayment/prepayment of certain of our borrowings
IPO - Anchor Investors
Windlas Biotech mobilises Rs 120.46 crore from 22 anchor investors ahead of IPO
Marquee investors who participated in the anchor book were Macquarie, Optimix Wholesale Global Emerging Markets, Invesco Trustee, Kuber India Fund, and Elara India Opportunities Fund.
Among others, ICICI Prudential, Nippon India, UTI MF, Sundaram MF, BNP Paribas, Avendus MF, and Canara HSBC also invested in the company
IPO - FAQs
Ans. Windlas Biotech Limited IPO is a Mainboard IPO. The issue is priced at ₹448-460 per equity share. The minimum order quantity is 30 Shares. The IPO opens on Aug 4, 2021, and closes on Aug 6, 2021. Link Intime India Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Ans. The Windlas Biotech Limited IPO opens on Aug 4, 2021 and closes on Aug 6, 2021.
Ans. You can track the real-time subscription numbers using the links below:
Ans. The size of Windlas Biotech Limited IPO is ₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares.
Ans. The Windlas Biotech Limited IPO price band is set between ₹448-460 per equity share.
Ans. To apply for Windlas Biotech Limited IPO, follow the steps given below:
- - Open the IPO Ji App or Website
- - Find Windlas Biotech Limited IPO in the List of IPOs
- - Press Apply Button
- - Select Your Demat Account
- - Select Your Shares Quantity and Submit
- - Track Your IPO Status
Ans. The share allotment date of Windlas Biotech Limited IPO is Aug 11, 2021.
Ans. The Windlas Biotech Limited IPO will be listed on Aug 16, 2021.
Ans. Follow the steps to check the Windlas Biotech Limited IPO allotment status online.
